ClinicalTrials.gg
CompletedNCT02685709MPOWEREDUpdated Apr 22, 2022Results posted

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

A Phase 3 interventional study of Octreotide capsules in Acromegaly, sponsored by Chiasma, Inc.. Completed at 53 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-22.

Sponsored by Chiasma, Inc. (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Enrollment
4th of 25
146 · median 56
Started
2016
the only one that year
Phase 3
12 of 25
1 open now
Registered
20th of 25
by date
Lead sponsor
3 of 25
Chiasma, Inc.

Among the 25 studies testing octreotide in Acromegaly, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 12 in phase 3, and was the 20th registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial (OPTMAL; NCT03252353), oral octreotide capsules demonstrated sustained biochemical response up to 13 months in patients with acromegaly previously managed with somatostatin analog injections (ref).

The objective of this study was to compare the efficacy, safety, and patient reported outcomes (PROs) between oral octreotide capsules and injectable somatostatin receptor ligands (SRLs).

Read the detailed description

This was phase 3, randomized, open-label, active controlled, multicenter study to evaluate the maintenance of response, safety and patient reported outcomes (PROs) in acromegaly patients treated with octreotide capsules and in patients treated with standard of care parenteral somatostatin receptor ligands (SRLs), who previously tolerated and demonstrated biochemical control on both treatments.

The core study consisted of three phases: a Screening phase, Run-in phase and a Randomized Controlled Treatment (RCT) phase.

Eligible patients who were biochemically controlled on parenteral SRLs were switched to octreotide capsules for a 26-week period Run-in phase. During this phase the effective dose for each patient was determined through dose titration.

Patients whose acromegaly has been controlled biochemically on octreotide capsules at the end of the Run-in phase entered a 36-week open-label RCT phase, where they randomized to continue on octreotide capsules or switch back to their injectable SRL treatment (as received prior to Screening).

Following the completion of the core study (Screening, Run-in and RCT phases), eligible patients were offered to enter the Study Extension phase and receive octreotide capsules until product marketing or study termination.

A Sub-study, performed in selected non-European sites, allowed patients with inadequate biochemical control on octreotide capsules during the Run-in phase to enter a Combination phase and receive co-administration of octreotide capsules with cabergoline tablets for a total of 36 weeks.

03

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Octreotide Capsules
  • Acromegaly
  • somatostatin receptor ligands (SRLs)
  • Mpowered
  • OOC-ACM-302
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of acromegaly
  • Treatment with Somatostatin analogs injections (octreotide or lanreotide) for at least 6 months
  • Biochemical control (IGF -1 \< 1.3 x and GH \< 2.5ng/mL)

Exclusion criteria

Exclusion Criteria:

  • Injections of long-acting somatostatin analogs, at a dosing interval > 8 weeks.
  • Pituitary radiotherapy within 5 years
  • Pituitary surgery within six months
  • Patients who previously participated in CH-ACM-01 study
  • Any uncontrolled concomitant disease
  • Symptomatic cholelithiasis
  • Previous treatment with:
  • Pegvisomant, within 12 weeks
  • Dopamine agonists, within 6 weeks
  • Pasireotide, within 12 weeks
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Run-in phase

    Oral octreotide capsules

    Drug: Octreotide capsules

  • Experimental
    RCT phase - Oral

    Oral octreotide capsules

    Drug: Octreotide capsules

  • Active comparator
    RCT phase - Injectables

    Injectable somatostatin analogs (octreotide or lanreotide)

    Drug: Octreotide capsules

  • Experimental
    Combination phase (sub-study)

    Octreotide capsules plus cabergoline

    Drug: Octreotide capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase

    Proportion of patients who are biochemically controlled throughout the RCT phase. A patient was considered biochemically controlled if IGF-1 Time Weighted Average (TWA) during the RCT phase is \<1.3 ULN

    Time frame: 62 weeks

Secondary outcomes

  1. Proportion of Patients With Clinical and Biochemical Control at the End of the RCT Phase

    Proportion of patients with clinical and biochemical control at the end of the RCT phase. Patients were considered biochemically and clinically controlled if they met both of the following criteria: * Their IGF-1 TWA during the RCT phase was \<1.3 times ULN * Their AIS score at week 62/EOT was maintained or reduced compared to week 26 (start of RCT phase)

    Time frame: Week 62/ End of treatment; EOT

  2. Proportion of Patients Who Maintain or Reduce the Overall Number of Active Acromegaly Symptoms at the End of the RCT Phase

    Proportion of patients who maintain or reduce the overall number of active acromegaly symptoms at the end of the RCT phase (week 62/ EOT) , compared to week 26 (start of the RCT phase

    Time frame: 62 weeks

  3. Proportion of Patients Who Maintain or Improve Their Overall Acromegaly Index of Severity (AIS) Score at the End of the RCT Phase

    Proportion of patients who maintain or improve their overall Acromegaly index of severity (AIS) score at the end of the RCT phase (improvement defined as a reduction of at least one point in the AIS score), compared to week 26 (start of the RCT phase)

    Time frame: 62 weeks

  4. Proportion of Patients of Those Completing the RCT Phase Who Entered the Study Extension Phase

    Proportion of patients of those completing the RCT phase (at a time octreotide capsules were not commercially available at the specific country), who entered the Study Extension phase, overall and by treatment group

    Time frame: 62 weeks

  5. Change in IGF-1 Levels in the RCT Phase

    Change in IGF-1 levels from the start of the randomized phase to the end of RCT phase. Complete Responder (CR) is defined as IGF-1 ≤ 1 x ULN; Partial Responder (PR) is defined as 1 x ULN \< IGF-1 \< 1.3 x ULN, and Non-Responder (NR): IGF-1 ≥ 1.3 x ULN

    Time frame: Change from Week 26 to week 62

  6. Change in GH Levels in the RCT Phase

    Change in GH levels from the start of the randomized phase through the end of RCT phase.

    Time frame: Change from Week 26 to week 62

Other outcomes

  1. Proportion of Patients Reporting Injection Site Reactions in the Acro-TSQ During the RCT Phase

    Proportion of patients reporting injection site reactions (ISRs). Acromegaly treatment satisfaction questionnaire (ACRO-TSQ) is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive ACRO-TSQ change scores indicate improvement while negative change scores indicate worsening.

    Time frame: 62 weeks

  2. Proportion of Patients Reporting Interference With Daily Activities in Acro-TSQ During the RCT Phase

    Proportion of patients reporting interference with daily activities in the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) during the RCT phase. Acro-TSQ is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive Acro-TSQ change scores indicate improvement while negative change scores indicate worsening.

    Time frame: 62 weeks

  3. Proportion of Patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Analysis

    Proportion of patients on octreotide capsules who are biochemically controlled at the end of the RCT phase defined as IGF-1\< 1.3 x ULN based on average of weeks 58 and 62

    Time frame: Average of weeks 58 and 62

  4. Proportion of Week 26 Responders on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Sensitivity Analysis

    Proportion of patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark sensitivity analysis- Week 26 responders

    Time frame: 62 weeks

  5. Proportion of Patients Biochemically Controlled at the End of Run-in

    Proportion of patients biochemically controlled at the end of the Run-in phase, defined as average IGF-1 levels during weeks 24 and 26 \< 1.3xULN

    Time frame: 26 weeks

  6. Proportion of Patients With a Reduction in the Overall Number of Active Acromegaly Symptoms at the End of the Run-in Phase

    Proportion of patients with a reduction in the overall number of active acromegaly symptoms at the end of the Run-in phase compared to Baseline

    Time frame: 26 weeks

  7. Proportion of Patients With Improved Acromegaly Index of Severity (AIS) Score at the End of the Run-in Phase

    Proportion of patients with improved AIS score at the end of the Run-in phase compared to Baseline Acromegaly index of severity (AIS) at the end of Run-in phase compared to Baseline. The Acromegaly Index of Severity (AIS) symptom score is calculated based on the presence and severity of 5 acromegaly signs/symptoms: headache, swelling of extremities, joint pain, sweating, and fatigue. Each symptom was graded from no symptoms (score 0), to mild symptoms (1), moderate (2), or severe symptoms (3).

    Time frame: 26 weeks

  8. EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Index Scores During the Run-in Phase

    Change from baselines in EQ-5D-5L Index scores in randomized participants during the Run-in phase. EQ-5D-5L (five severity levels EQ-5D) is a standardized instrument completed by the patient for use as a measure of health outcome applicable to a wide range of health conditions. It comprises 5 dimensions of health: mobility, ability to self care, ability to undertake usual activities, pain and discomfort, and anxiety and depression. Based on qualitative and quantitative studies conducted by the EuroQol Group, there are 5 levels under each domain: 'no problems' (assigned a value of 1), 'slight problems' (assigned a value of 2), 'moderate problems' (assigned a value of 3), 'severe problems' (assigned a value of 4), and 'unable to/extreme problems' (assigned a value of 5). An EQ-5D Index score is calculated based on the responses to these 5 dimensions of health. Weights for use in the index calculation are not universally available. Higher values represent better health states.

    Time frame: 26 weeks

  9. Change From Baseline to End of RCT Phase in WPAI

    Work Productivity and Activity Impairment Questionnaire- RCT phase. WPAI:SHP is a standardized and validated PRO questionnaire to measure health outcomes in clinical trial settings. It measures time missed from work, impairment of work and regular activities due to overall health and symptoms, relative to measures of general health perceptions, role (physical), role (emotional), pain, symptom severity, and global measures of work and interference with regular activity. The WPAI yields 4 types of scores: (1) absenteeism (work time missed); (2) presenteeism (impairment at work/reduced on-the-job effectiveness); (3) work productivity loss (overall work impairment/absenteeism plus presenteeism); and (4) activity impairment. Each of the 4 WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity (i.e., worse outcomes).

    Time frame: 26 weeks

  10. Change From Baseline to End of Run-in Phase in WPAI

    Work Productivity and Activity Impairment Questionnaire- Run-in phase. WPAI:SHP is a standardized and validated PRO questionnaire to measure health outcomes in clinical trial settings. It measures time missed from work, impairment of work and regular activities due to overall health and symptoms, relative to measures of general health perceptions, role (physical), role (emotional), pain, symptom severity, and global measures of work and interference with regular activity. The WPAI yields 4 types of scores: (1) absenteeism (work time missed); (2) presenteeism (impairment at work/reduced on-the-job effectiveness); (3) work productivity loss (overall work impairment/absenteeism plus presenteeism); and (4) activity impairment. Each of the 4 WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity (i.e., worse outcomes).

    Time frame: 62 weeks

  11. Change in Acromegaly Treatment Satisfaction Questionnaire (ACRO-TSQ) Scores From Baseline to End of Run-in in Randomized Patients.

    Change in Acromegaly treatment satisfaction questionnaire (ACRO-TSQ) PRO questionnaire from baseline to end of Run-in phase in randomized patients. Acro-TSQ is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive Acro-TSQ change scores indicate improvement while negative change scores indicate worsening.

    Time frame: 26 weeks

07

Results

Posted Apr 22, 2022

Participant flow

146 patients were enrolled into the Run-in phase. A total of 116 patients completed the Run-in phase and 30 patients discontinued the Run in phase. Of the 116 patients who completed the Run-in phase, 92 patients with IGF-1\<1.3 ULN entered the RCT phase, 11 patients with IGF-1≥1.3 and \<2 ULN on the highest octreotide dose entered the Combination phase, and 13 patients did not continue treatment.

Run-in Phase
Participant flow — Run-in Phase
MilestoneRun-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)
Started146000
Completed116000
Not completed30000
RCT Phase
Participant flow — RCT Phase
MilestoneRun-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)
Started055370
Completed054350
Not completed0120
Combination Phase
Participant flow — Combination Phase
MilestoneRun-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)
Started00014
Completed0008
Not completed0006

Outcome measures

PrimaryProportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase

Proportion of patients who are biochemically controlled throughout the RCT phase. A patient was considered biochemically controlled if IGF-1 Time Weighted Average (TWA) during the RCT phase is \<1.3 ULN

Time frame:
62 weeks
Reported as:
Count of participants · Participants
Proportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase
ParticipantsRCT Phase - OralRCT Phase - Injectables
Proportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase5037
Statistical analysis
  • RCT Phase - Oral vs RCT Phase - Injectables · Stratified Miettinen & Nurminen (M&N) · 95% ci stratified miettinen & nurminen: -19.9 · 95% CI -19.9 to 0.5
SecondaryProportion of Patients With Clinical and Biochemical Control at the End of the RCT Phase

Proportion of patients with clinical and biochemical control at the end of the RCT phase. Patients were considered biochemically and clinically controlled if they met both of the following criteria: * Their IGF-1 TWA during the RCT phase was \<1.3 times ULN * Their AIS score at week 62/EOT was maintained or reduced compared to week 26 (start of RCT phase)

Time frame:
Week 62/ End of treatment; EOT
Reported as:
Count of participants · Participants
Proportion of Patients With Clinical and Biochemical Control at the End of the RCT Phase
ParticipantsRCT Phase - OralRCT Phase - Injectables
Proportion of Patients With Clinical and Biochemical Control at the End of the RCT Phase3627
Statistical analysis
  • RCT Phase - Oral vs RCT Phase - Injectables ·
SecondaryProportion of Patients Who Maintain or Reduce the Overall Number of Active Acromegaly Symptoms at the End of the RCT Phase

Proportion of patients who maintain or reduce the overall number of active acromegaly symptoms at the end of the RCT phase (week 62/ EOT) , compared to week 26 (start of the RCT phase

Time frame:
62 weeks
Reported as:
Count of participants · Participants
Proportion of Patients Who Maintain or Reduce the Overall Number of Active Acromegaly Symptoms at the End of the RCT Phase
ParticipantsRCT Phase - OralRCT Phase - Injectables
Proportion of Patients Who Maintain or Reduce the Overall Number of Active Acromegaly Symptoms at the End of the RCT Phase4126
Statistical analysis
  • RCT Phase - Oral vs RCT Phase - Injectables · Clopper-Pearson method
SecondaryProportion of Patients Who Maintain or Improve Their Overall Acromegaly Index of Severity (AIS) Score at the End of the RCT Phase

Proportion of patients who maintain or improve their overall Acromegaly index of severity (AIS) score at the end of the RCT phase (improvement defined as a reduction of at least one point in the AIS score), compared to week 26 (start of the RCT phase)

Time frame:
62 weeks
Reported as:
Count of participants · Participants
Proportion of Patients Who Maintain or Improve Their Overall Acromegaly Index of Severity (AIS) Score at the End of the RCT Phase
ParticipantsRCT Phase - OralRCT Phase - Injectables
Proportion of Patients Who Maintain or Improve Their Overall Acromegaly Index of Severity (AIS) Score at the End of the RCT Phase4025
Statistical analysis
  • RCT Phase - Oral vs RCT Phase - Injectables ·
SecondaryProportion of Patients of Those Completing the RCT Phase Who Entered the Study Extension Phase

Proportion of patients of those completing the RCT phase (at a time octreotide capsules were not commercially available at the specific country), who entered the Study Extension phase, overall and by treatment group

Time frame:
62 weeks
Reported as:
Count of participants · Participants
Proportion of Patients of Those Completing the RCT Phase Who Entered the Study Extension Phase
ParticipantsRCT Phase - OralRCT Phase - Injectables
Proportion of Patients of Those Completing the RCT Phase Who Entered the Study Extension Phase3418
Statistical analysis
  • RCT Phase - Oral vs RCT Phase - Injectables · Clopper-Pearson method
SecondaryChange in IGF-1 Levels in the RCT Phase

Change in IGF-1 levels from the start of the randomized phase to the end of RCT phase. Complete Responder (CR) is defined as IGF-1 ≤ 1 x ULN; Partial Responder (PR) is defined as 1 x ULN \< IGF-1 \< 1.3 x ULN, and Non-Responder (NR): IGF-1 ≥ 1.3 x ULN

Time frame:
Change from Week 26 to week 62
Reported as:
Mean · x Upper limit of normal ("ULN")
Change in IGF-1 Levels in the RCT Phase
x Upper limit of normal ("ULN")RCT Phase - OralRCT Phase - Injectables
Change in IGF-1 Levels in the RCT Phase-0.01 ± 0.199-0.04 ± 0.133
Statistical analysis
  • RCT Phase - Oral vs RCT Phase - Injectables ·
SecondaryChange in GH Levels in the RCT Phase

Change in GH levels from the start of the randomized phase through the end of RCT phase.

Time frame:
Change from Week 26 to week 62
Reported as:
Mean · ng/mL
Change in GH Levels in the RCT Phase
ng/mLRCT Phase - OralRCT Phase - Injectables
Change in GH Levels in the RCT Phase-0.02 ± 0.5060.27 ± 1.219
Statistical analysis
  • RCT Phase - Oral vs RCT Phase - Injectables ·
Other pre-specifiedProportion of Patients Reporting Injection Site Reactions in the Acro-TSQ During the RCT Phase

Proportion of patients reporting injection site reactions (ISRs). Acromegaly treatment satisfaction questionnaire (ACRO-TSQ) is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive ACRO-TSQ change scores indicate improvement while negative change scores indicate worsening.

Time frame:
62 weeks
Reported as:
Count of participants · Participants
Proportion of Patients Reporting Injection Site Reactions in the Acro-TSQ During the RCT Phase
ParticipantsRCT Phase - OralRCT Phase - Injectables
Proportion of Patients Reporting Injection Site Reactions in the Acro-TSQ During the RCT Phase017
Statistical analysis
  • RCT Phase - Oral vs RCT Phase - Injectables ·
Other pre-specifiedProportion of Patients Reporting Interference With Daily Activities in Acro-TSQ During the RCT Phase

Proportion of patients reporting interference with daily activities in the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) during the RCT phase. Acro-TSQ is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive Acro-TSQ change scores indicate improvement while negative change scores indicate worsening.

Time frame:
62 weeks
Reported as:
Count of participants · Participants
Proportion of Patients Reporting Interference With Daily Activities in Acro-TSQ During the RCT Phase
ParticipantsRCT Phase - OralRCT Phase - Injectables
Proportion of Patients Reporting Interference With Daily Activities in Acro-TSQ During the RCT Phase013
Statistical analysis
  • RCT Phase - Oral vs RCT Phase - Injectables ·
Other pre-specifiedProportion of Patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Analysis

Proportion of patients on octreotide capsules who are biochemically controlled at the end of the RCT phase defined as IGF-1\< 1.3 x ULN based on average of weeks 58 and 62

Time frame:
Average of weeks 58 and 62
Reported as:
Count of participants · Participants
Proportion of Patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Analysis
ParticipantsRCT Phase - OralRCT Phase - Injectables
Proportion of Patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Analysis4935
Statistical analysis
  • RCT Phase - Oral vs RCT Phase - Injectables ·
Other pre-specifiedProportion of Week 26 Responders on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Sensitivity Analysis

Proportion of patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark sensitivity analysis- Week 26 responders

Time frame:
62 weeks
Reported as:
Count of participants · Participants
Proportion of Week 26 Responders on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Sensitivity Analysis
ParticipantsRCT Phase - OralRCT Phase - Injectables
Proportion of Week 26 Responders on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Sensitivity Analysis4534
Statistical analysis
  • RCT Phase - Oral vs RCT Phase - Injectables ·
Other pre-specifiedProportion of Patients Biochemically Controlled at the End of Run-in

Proportion of patients biochemically controlled at the end of the Run-in phase, defined as average IGF-1 levels during weeks 24 and 26 \< 1.3xULN

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Proportion of Patients Biochemically Controlled at the End of Run-in
ParticipantsRun-in Phase
Proportion of Patients Biochemically Controlled at the End of Run-in94
Statistical analysis
  • Run-in Phase · Proportion of patients: 64.4 · 95% CI 56 to 72.1Confidence Interval estimated using the Clopper-Pearson (Exact) method.
Other pre-specifiedProportion of Patients With a Reduction in the Overall Number of Active Acromegaly Symptoms at the End of the Run-in Phase

Proportion of patients with a reduction in the overall number of active acromegaly symptoms at the end of the Run-in phase compared to Baseline

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Proportion of Patients With a Reduction in the Overall Number of Active Acromegaly Symptoms at the End of the Run-in Phase
ParticipantsRun-in Phase
Proportion of Patients With a Reduction in the Overall Number of Active Acromegaly Symptoms at the End of the Run-in Phase97
Statistical analysis
  • Run-in Phase · Proportion of patients: 66.4 · 95% CI 58.5 to 74.1
Other pre-specifiedProportion of Patients With Improved Acromegaly Index of Severity (AIS) Score at the End of the Run-in Phase

Proportion of patients with improved AIS score at the end of the Run-in phase compared to Baseline Acromegaly index of severity (AIS) at the end of Run-in phase compared to Baseline. The Acromegaly Index of Severity (AIS) symptom score is calculated based on the presence and severity of 5 acromegaly signs/symptoms: headache, swelling of extremities, joint pain, sweating, and fatigue. Each symptom was graded from no symptoms (score 0), to mild symptoms (1), moderate (2), or severe symptoms (3).

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Proportion of Patients With Improved Acromegaly Index of Severity (AIS) Score at the End of the Run-in Phase
ParticipantsRun-in Phase
Proportion of Patients With Improved Acromegaly Index of Severity (AIS) Score at the End of the Run-in Phase45
Statistical analysis
  • Run-in Phase · Proportion of patients: 48.9 · 95% CI 38.7 to 59.1
Other pre-specifiedEuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Index Scores During the Run-in Phase

Change from baselines in EQ-5D-5L Index scores in randomized participants during the Run-in phase. EQ-5D-5L (five severity levels EQ-5D) is a standardized instrument completed by the patient for use as a measure of health outcome applicable to a wide range of health conditions. It comprises 5 dimensions of health: mobility, ability to self care, ability to undertake usual activities, pain and discomfort, and anxiety and depression. Based on qualitative and quantitative studies conducted by the EuroQol Group, there are 5 levels under each domain: 'no problems' (assigned a value of 1), 'slight problems' (assigned a value of 2), 'moderate problems' (assigned a value of 3), 'severe problems' (assigned a value of 4), and 'unable to/extreme problems' (assigned a value of 5). An EQ-5D Index score is calculated based on the responses to these 5 dimensions of health. Weights for use in the index calculation are not universally available. Higher values represent better health states.

Time frame:
26 weeks
Reported as:
Mean · units on a scale
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Index Scores During the Run-in Phase
units on a scaleRun-in Phase
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Index Scores During the Run-in Phase0.0433 (0.011 to 0.0755)
Other pre-specifiedChange From Baseline to End of RCT Phase in WPAI

Work Productivity and Activity Impairment Questionnaire- RCT phase. WPAI:SHP is a standardized and validated PRO questionnaire to measure health outcomes in clinical trial settings. It measures time missed from work, impairment of work and regular activities due to overall health and symptoms, relative to measures of general health perceptions, role (physical), role (emotional), pain, symptom severity, and global measures of work and interference with regular activity. The WPAI yields 4 types of scores: (1) absenteeism (work time missed); (2) presenteeism (impairment at work/reduced on-the-job effectiveness); (3) work productivity loss (overall work impairment/absenteeism plus presenteeism); and (4) activity impairment. Each of the 4 WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity (i.e., worse outcomes).

Time frame:
26 weeks
Reported as:
Least squares mean · Percentage change from Baseline RCT
Change From Baseline to End of RCT Phase in WPAI
Percentage change from Baseline RCTRCT Phase - OralRCT Phase - Injectables
Absenteeism (%)-0.34 (-2.11 to 1.43)0.79 (-1.53 to 3.12)
Presenteeism (%)1.85 (-4.48 to 8.17)5.98 (-2.02 to 13.98)
Work productivity loss (%)1.49 (-5.09 to 8.08)6.93 (-1.74 to 15.59)
Activity impairment (%)0.84 (-4.34 to 6.02)4.34 (-2.1 to 10.77)
Other pre-specifiedChange From Baseline to End of Run-in Phase in WPAI

Work Productivity and Activity Impairment Questionnaire- Run-in phase. WPAI:SHP is a standardized and validated PRO questionnaire to measure health outcomes in clinical trial settings. It measures time missed from work, impairment of work and regular activities due to overall health and symptoms, relative to measures of general health perceptions, role (physical), role (emotional), pain, symptom severity, and global measures of work and interference with regular activity. The WPAI yields 4 types of scores: (1) absenteeism (work time missed); (2) presenteeism (impairment at work/reduced on-the-job effectiveness); (3) work productivity loss (overall work impairment/absenteeism plus presenteeism); and (4) activity impairment. Each of the 4 WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity (i.e., worse outcomes).

Time frame:
62 weeks
Reported as:
Least squares mean · Percentage change from Run-in baseline
Change From Baseline to End of Run-in Phase in WPAI
Percentage change from Run-in baselineRun-in Phase
Absenteeism (%)-0.81 (-3.84 to 2.21)
Presenteeism (%)-6.65 (-12.39 to -0.9)
Work Productivity Loss (%)-6.92 (-12.83 to -1.02)
Activity Impairment (%)-4.94 (-9.17 to -0.71)
Other pre-specifiedChange in Acromegaly Treatment Satisfaction Questionnaire (ACRO-TSQ) Scores From Baseline to End of Run-in in Randomized Patients.

Change in Acromegaly treatment satisfaction questionnaire (ACRO-TSQ) PRO questionnaire from baseline to end of Run-in phase in randomized patients. Acro-TSQ is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive Acro-TSQ change scores indicate improvement while negative change scores indicate worsening.

Time frame:
26 weeks
Reported as:
Mean · score on a scale
Change in Acromegaly Treatment Satisfaction Questionnaire (ACRO-TSQ) Scores From Baseline to End of Run-in in Randomized Patients.
score on a scaleRun-in Phase
Emotional reaction - Change from baseline9.65 (3.31 to 15.98)
GI interference - Change from baseline4.24 (-1.32 to 9.8)
Symptom interference- Change from baseline2.45 (-2.1 to 7)
Treatment convenience - Change from baseline6.37 (0.25 to 12.5)
Treatment satisfaction - Change from baseline6.73 (0.9 to 12.55)
Statistical analysis
  • Run-in Phase ·

Adverse events

Collected over 1 year, 3 months for both the Run-in and RCT phases.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in Phase0/146 (0%)6/146 (4.1%)106/146 (72.6%)
RCT Phase - Oral1/55 (1.8%)3/55 (5.5%)39/55 (70.9%)
RCT Phase - Injectables0/37 (0%)3/37 (8.1%)26/37 (70.3%)
Combination Phase (Sub-study)0/14 (0%)0/14 (0%)11/14 (78.6%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventRun-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)
Acute myocardial infarctionCardiac disorders0/1461/551/370/14
Sinus bradycardiaCardiac disorders0/1460/551/370/14
CholelithiasisHepatobiliary disorders0/1460/551/370/14
PericarditisCardiac disorders0/1461/550/370/14
Toxicity to various agentsInjury, poisoning and procedural complications0/1461/550/370/14
Atrial flutterCardiac disorders1/1460/550/370/14
Cardiac failureCardiac disorders1/1460/550/370/14
Cardiac failure congestiveCardiac disorders1/1460/550/370/14
Cholecystitis acuteHepatobiliary disorders1/1460/550/370/14
Post cholecystectomy syndromeHepatobiliary disorders1/1460/550/370/14
Most frequent other events
Showing 10 of 33
Most frequent other events
EventRun-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)
FlatulenceGastrointestinal disorders14/14614/558/371/14
NauseaGastrointestinal disorders32/14611/553/372/14
DiarrheaGastrointestinal disorders22/1466/555/371/14
ConstipationGastrointestinal disorders5/1463/555/370/14
Injection site noduleGeneral disorders0/1460/555/370/14
HeadacheNervous system disorders18/1465/551/370/14
ErythemaSkin and subcutaneous tissue disorders0/1460/554/370/14
Abdominal painGastrointestinal disorders13/1465/553/370/14
NasopharyngitisInfections and infestations9/1465/550/371/14
ArthralgiaMusculoskeletal and connective tissue disorders6/1465/552/370/14

Baseline characteristics

Acromegaly patients who previously tolerated and demonstrated a biochemical control on SRLs

Age, Categorical
Age, Categorical(Participants)Run-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)Total
Run-in phase — <=18 years00000
Run-in phase — Between 18 and 65 years124000124
Run-in phase — >=65 years2200022
RCT phase — <=18 years00000
RCT phase — Between 18 and 65 years04632078
RCT phase — >=65 years095014
Combination Phase — <=18 years00000
Combination Phase — Between 18 and 65 years0001111
Combination Phase — >=65 years00033
Age, Continuous
Age, Continuous(years)Run-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)Total
Run-in phase54.1 ± 10.5———54.1 ± 10.5
RCT phase—54.1 ± 10.8855.2 ± 8.78—54.5 ± 10.05
Combination phase———59.8 ± 5.8259.8 ± 5.82
Sex: Female, Male
Sex: Female, Male(Participants)Run-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)Total
Run-in phase — Female9400094
Run-in phase — Male5200052
RCT phase — Female03526061
RCT phase — Male02011031
Combination phase — Female0001010
Combination phase — Male00044
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Run-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)Total
Run-in phase — Hispanic or Latino50005
Run-in phase — Not Hispanic or Latino130000130
Run-in phase — Unknown or Not Reported1100011
RCT phase — Hispanic or Latino01203
RCT phase — Not Hispanic or Latino05033083
RCT phase — Unknown or Not Reported04206
Combination phase — Hispanic or Latino00000
Combination phase — Not Hispanic or Latino0001414
Combination phase — Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Run-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)Total
Run-in phase — American Indian or Alaska Native00000
Run-in phase — Asian10001
Run-in phase — Native Hawaiian or Other Pacific Islander00000
Run-in phase — Black or African American30003
Run-in phase — White133000133
Run-in phase — More than one race90009
Run-in phase — Unknown or Not Reported00000
RCT phase — American Indian or Alaska Native00000
RCT phase — Asian00000
RCT phase — Native Hawaiian or Other Pacific Islander00000
RCT phase — Black or African American02002
RCT phase — White04935084
RCT phase — More than one race04206
RCT phase — Unknown or Not Reported00000
Combination phase — American Indian or Alaska Native00000
Combination phase — Asian00000
Combination phase — Native Hawaiian or Other Pacific Islander00000
Combination phase — Black or African American00000
Combination phase — White0001414
Combination phase — More than one race00000
Combination phase — Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Run-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)Total
Hungary3———3
United States37———37
Spain6———6
Russia65———65
Austria6———6
Italy2———2
France10———10
Lithuania8———8
Serbia8———8
Germany1———1
Region of Enrollment
Region of Enrollment(Participants)Run-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)Total
Hungary—11—2
United States—1410—24
Spain—13—4
Russia—2418—42
Austria—50—5
Italy—10—1
France—42—6
Lithuania—11—2
Serbia—42—6
Region of Enrollment
Region of Enrollment(Participants)Run-in PhaseRCT Phase - OralRCT Phase - InjectablesCombination Phase (Sub-study)Total
United States———33
Russia———1010
Serbia———11

4 further baseline measures are reported on the registry.

08

Study locations

53 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Keck Medical Center of University of Southern California
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • John H. Stroger, Jr. Hospital of Cook County
    Chicago, Illinois 60612, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Rutgers - Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08903, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43203, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Allegheny Endocrinology Associates
    Pittsburgh, Pennsylvania 15212, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Houston Methodist Research Institute
    Houston, Texas 77030, United States
  • Universitätsklinik für Innere Medizin Klinische Abteilung für Endokrinologie und Diabetologie
    Graz, A-8036, Austria
  • Medizinische Universität Wien
    Wien, A-1090, Austria
  • Hospices Civils de Lyon
    Bron, 69677, France
  • Hôpital Bicêtre APHP
    Le Kremlin-Bicêtre, 94275, France
  • Praxis für Endokrinologie und Diabetologie Dr M Droste
    Oldenburg, 26122, Germany
  • Magyar Honvedseg Egeszsegugyi Kozpont
    Budapest, H-1062, Hungary
  • University of Pecs
    Pecs, H-7624, Hungary
  • Szegedi Tudományegyetem, I. Belgyógyászati Klinika
    Szeged, H-6720, Hungary
  • Policlinico di Monserrato U.O.C. Endocrinologia e Diabetologia
    Monserrato, 09042, Italy
  • Università di Pisa Dipartimento di Medicina Clinica e Sperimentale
    Pisa, 56124, Italy
  • Fondazione Policlinico Universitario A. Gemelli Università Cattolica del S.Cuore S.C. Endocrinologia e Malattie del Metabolismo
    Rome, 00168, Italy
  • Hospital of LUHS Kauno Klinikos
    Kaunas, LT-50009, Lithuania
  • Vaidotas Urbanavicius Individuali Imonė
    Vilnius, LT-10207, Lithuania
  • Katedra i Klinika Endokrynologii i Chorob Wewnetrznych Gdanski Uniwersytet Medyczny
    Gdańsk, 80-211, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Klinika Endokrynologii, Diabetologii i Leczenia Izotopami
    Wroclaw, 50-367, Poland
  • "C.I. Parhon" National Institute of Endocrinology I Clinical Endocrinology Department - Endemic goitier and its complications
    Bucharest, 011863, Romania
  • Antrium Multidisciplinary Medical Clinic
    Barnaul, 656043, Russian Federation
  • Interregional Clinical Diagnostic Center
    Kazan, 420101, Russian Federation
  • Regional State Budgetary Healthcare Institution Regional State Hospital
    Krasnoyarsk, 660022, Russian Federation
  • Sechenov Moscow First State Medical University
    Moscow, 119881, Russian Federation
  • "Atlas" Medical Center
    Moscow, 121170, Russian Federation
  • Vladimirsky Moscow Regional Research Clinical Institute
    Moscow, 129110, Russian Federation
  • Novosibirsk State Regional Clinical Hospital
    Novosibirsk, 630087, Russian Federation
  • Federal State Budgetary Institution "V. A. Almazov Federal North-West Medical Research Centre" of the Ministry of Health of the Russian Federation
    Saint-Petersburg, 194156, Russian Federation
  • "Centre Diabetes" LLC
    Samara, 443041, Russian Federation
  • Clinical Centre of Serbia, Clinic for Endocrinology Diabetes and Metabolic Diseases
    Belgrade, 11 000, Serbia
  • Hospital Universitario de la Ribera
    Alzira, 46600, Spain
  • Hospital Universitari Germans Trias i Pujol
    Barcelona, 08916, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Complejo Hospitalario Universitario de Santiago de Compostela
    Santiago de Compostela, 15706, Spain
  • Campus Del Hospital Universitario Virgen del Rocio
    Sevilla, 46013, Spain
  • University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital
    Birmingham, B15 2GW, United Kingdom
  • Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary
    Manchester, M13 9WL, United Kingdom
  • Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • Royal Hallamshire Hospital
    Sheffield, S10 2JF, United Kingdom
09

References and documents

Publications

  • Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein MD, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger C. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015 Apr;100(4):1699-708. doi: 10.1210/jc.2014-4113. Epub 2015 Feb 9. Erratum In: J Clin Endocrinol Metab. 2016 Oct;101(10):3863. doi: 10.1210/jc.2016-4113. J Clin Endocrinol Metab. 2020 Dec 1;105(12):dgaa637. doi: 10.1210/clinem/dgaa637. PubMed 25664604 ↗
  • Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol. 2016 Feb;12(2):90-8. doi: 10.1038/nrendo.2015.196. Epub 2015 Nov 27. PubMed 26610414 ↗
  • Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2022 Feb;10(2):102-111. doi: 10.1016/S2213-8587(21)00296-5. Epub 2021 Dec 22. Erratum In: Lancet Diabetes Endocrinol. 2022 Mar;10(3):e3. doi: 10.1016/S2213-8587(22)00051-1. PubMed 34953531 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Oct 2020, 56 months.

Results were first posted in Apr 2022, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2016
First posted
Feb 19, 2016
StartActual
Feb 2016
Primary completionActual
Oct 2020
CompletionActual
Aug 2021
Results first posted
Apr 22, 2022
Last update
Apr 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02685709
Lead sponsor
Chiasma, Inc.
Responsible party
Sponsor
First posted
Feb 19, 2016
Start date
Feb 2016
Primary completion
Oct 2020
Completion
Aug 2021
Results posted
Apr 22, 2022
Last update
Apr 22, 2022

Study contacts

Maria Fleseriu, M.D., FACE
study chair · Northwest Pituitary Center, Oregon Health & Science University , Portland, OR, USA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion